Phase IIb Pilot Study for the Evaluation of the Safety and the Feasibility of Treatment Simplification to Tenofovir+Emtricitabine+Raltegravir or to Lamivudine+Abacavir+Raltegravir in Patients With Optimal Virological Control and Toxicity to the Current Combined Antiretroviral Regimen.

Trial Profile

Phase IIb Pilot Study for the Evaluation of the Safety and the Feasibility of Treatment Simplification to Tenofovir+Emtricitabine+Raltegravir or to Lamivudine+Abacavir+Raltegravir in Patients With Optimal Virological Control and Toxicity to the Current Combined Antiretroviral Regimen.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2014

At a glance

  • Drugs Raltegravir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Lamivudine/abacavir
  • Indications HIV infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms RaSTA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Oct 2011 Subcutaneous fat and bone results presented at the 13th European AIDS Conference.
    • 15 Oct 2011 Results presented at the 13th European AIDS Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top